Glaukos Corporation
GKOS
株式のランク
#2039
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
株価
$172.48
時価総額
$10.17B
変化（1日）
3.41%
変化（1年）
117.03%
国
US
取引 Glaukos Corporation (GKOS)
カテゴリー
Healthcare
Glaukos Corporation（GKOS）のP/B比率
October 2026 時点のP/B比率 TTM: 14.37
Glaukos Corporation の最新の財務報告および株価によると、現在のP/B比率（TTM）は 14.37 です。2023 年末時点でのP/B比率は 8.34 でした。
Glaukos Corporation の P/B 比率の履歴（2012 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 14.37 | 39.39% |
| 2024 | 10.31 | 23.71% |
| 2023 | 8.34 | 113.23% |
| 2022 | 3.91 | 11.28% |
| 2021 | 3.51 | -29.97% |
| 2020 | 5.02 | 66.02% |
| 2019 | 3.02 | -73.28% |
| 2018 | 11.31 | 77.22% |
| 2017 | 6.38 | -33.74% |
| 2016 | 9.63 | 112.49% |
| 2015 | 4.53 | -188.26% |
| 2014 | -5.13 | -6.61% |
| 2013 | -5.50 | -74.41% |
| 2012 | -21.48 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 3.5116 | -75.56% |
US
|
|
| 2.0146 | -85.98% |
IE
|
|
| 4.5025 | -68.67% |
US
|
|
| 2.5486 | -82.27% |
US
|
|
| - | - |
DE
|
